Nexalin Technology, Inc.

Nexalin Technology, Inc.

NNASDAQ:NXL
1.56
USD
+0.08
(+5.41%)
-0.61EPS
Mar 03Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.03
0.03
0.24
0.02
0.02
0.02
0.01
Basic EPS, GAAP
-0.47
-1.24
-0.3
-0.63
-0.83
-0.5
-0.61
Free Cash Flow per Basic Share
-0.12
-0.22
-0.4
-0.54
-0.45
-0.31
-0.42
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.25
-0.26
0.75
0.43
0.28
0.2
0.07
Tangible Book Value per Share
-0.25
-0.26
0.75
0.42
0.26
0.18
0.02
Basic Weighted Avg Shares
7
5
6
7
9
16
15
Sales/Revenue/Turnover
- -
- -
1
- -
- -
- -
- -
Operating Margin (%)
-1,341.38
-4,177.7
-138.72
-5,143.48
-4,596.14
-2,781.69
-4,202.54
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-6
-2
-5
-8
-8
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,401.11
-4,218.93
-128.49
-4,197.56
-4,508.73
-2,725.76
-4,139.38
Working Capital
-1
-2
5
3
3
3
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
-2
-2
5
3
4
4
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-107.05
-221.05
-221.5
-240.25

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
21
22
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4
3
2
Cash, Cash Equivalents & STI
4
3
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-88.97%
1.96%
Free Cash Flow
- -
47.11%
22.84%
Net Income, GAAP
- -
50.41%
8.08%
Sales/Revenue/Turnover
- -
163.2%
78.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.17
-0.23
-6.39
-0.83
2025
-0.15
-0.1
-0.13
-3.83
-0.5
2026
-0.11
-0.11
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Mark White
Full Time Employees
8
Sector
Health technology
Industry
Medical specialties
Address
1776 Yorktown Houston TX United States 77056
IPO Date
Sep 16, 2022
Business
Nexalin Technology, Inc. (NXL) designs and develops non-invasive neurostimulation devices for treating mental health disorders including anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, Alzheimer's disease and dementia; its core products comprise Generation 1, a bioelectronic medical device for anxiety, insomnia and depression without drugs or psychotherapy, Generation 2 SYNC neurostimulation console and Generation 3 HALO Clarity headset utilizing proprietary waveforms to restore brain rhythms. Founded in 2010 and headquartered in Houston, Texas, the company operates primarily in the United States and China with recent international expansion. In November 2025, Nexalin appointed Carmi Masha Technologies Ltd. as exclusive distributor in Israel following regulatory approval for its Gen-2 SYNC 15 mA device; the company also completed an FDA Q-Submission meeting for the Gen-2 SYNC in its Alzheimer's program and received a U.S. patent for neurostimulation technology in September 2025.

Company News

  • Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease

  • Nuix Launches Agentic AI in Nuix Neo with Audit Trail Built In

  • Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis

  • Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

  • Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)

  • Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

  • Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

  • LogicMark (OTCMKTS:LGMKD) vs. Nexalin Technology (NASDAQ:NXL) Head to Head Comparison

  • Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study

  • Nexalin Technology Announces Reverse Stock Split

  • Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

  • Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

  • Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

  • Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

  • Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

  • Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

  • Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

  • Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

  • Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

  • Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21